



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/58, 9/12, 9/72</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/18971</b> <b>(43) International Publication Date:</b> 22 April 1999 (22.04.99)
<b>(21) International Application Number:</b> PCT/US98/20480 <b>(22) International Filing Date:</b> 6 October 1998 (06.10.98)  <b>(30) Priority Data:</b> 08/948,118                      9 October 1997 (09.10.97)                      US  <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US    08/948,118 (CON) Filed on    9 October 1997 (09.10.97)  <b>(71) Applicant (for all designated States except US):</b> SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HARRIS, David [GB/US]; 7 Lackawanna Boulevard, New Providence, NJ 07974 (US). SEQUEIRA, Joel, A. [US/US]; 6 Mary Ellen Drive, Edison, NJ 08820 (US). CHAUDRY, Imtiaz, A. [US/US]; 18 Rose Avenue, North Caldwell, NJ 07006 (US).		<b>(74) Agents:</b> FRANKS, Robert, A. et al.; Schering-Plough Corporation, Patent dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).  <b>(81) Designated States:</b> AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> MOMETASONE FUROATE SUSPENSIONS FOR NEBULIZATION  <b>(57) Abstract</b>  An aqueous nebulizer suspension contains water, mometasone furoate monohydrate, a nonionic surfactant, a soluble salt and optionally a pH buffer. The suspension may be prepared by ultrasonication or jet milling techniques.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KR	Democratic People's Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5

## MOMETASONE FUROATE SUSPENSIONS FOR NEBULIZATION

10

### INTRODUCTION TO THE INVENTION

15       The present invention relates to aqueous suspensions of water-insoluble pharmaceutical substances, and more particularly to suspensions of substances intended for inhalation therapy.

      Use of inhaled therapeutic substances has become common for the treatment of airway disorders, such disorders including, without limitation  
20   thereto, asthma, infections, emphysema and various inflammatory conditions. Substances commonly delivered to the lower airway surfaces, that is, the trachea, bronchial tree and lungs, by oral or nasal inhalation include bronchodilators, corticosteroids, anti-infectives and anti-inflammatory medicaments. Various methods have been used for such delivery, including  
25   pressurized metered dose inhalers, dry powder inhalers and nebulizers.

      Nebulizers are considered to be instruments generating very fine particles of a liquid in a gas. As is very well known, particles intended for treatment of the lower airway, i.e., the bronchial tree or the lungs, will generally be less than 10 micrometers in the largest dimension, to prevent unwanted  
30   deposition onto surfaces of the mouth and pharynx, and more preferably will be less than 5  $\mu\text{m}$ . In addition, particles much smaller than about 0.5  $\mu\text{m}$  in the largest dimension frequently are not easily deposited at the desired

location, and a large fraction of these simply will be exhaled by a patient. For these reasons, it is generally desired to produce particles which average 1-7  $\mu\text{m}$  in their largest dimension, while preferably minimizing production of particles having sizes either less than about 0.5 or greater than about 10  $\mu\text{m}$ .

5 The more preferred average particle sizes are in the range of 0.5-5  $\mu\text{m}$ .

Nebulization, although used more infrequently than other drug delivery techniques, has certain advantages for special patient groups, such as young children and the very infirm. Although somewhat cumbersome equipment is needed and there may be more stringent cleaning requirements than exist for  
10 some of the more popular delivery techniques, no particular patient skill or coordination is required: the patient merely needs to breathe normally to introduce the medication into the airway. Thus, treatment can be delivered even to an unconscious patient or an infant. It is also considered an advantage of nebulizers that quantities of moisture are delivered to the airway;  
15 this may help to fluidize secretions and tends to increase patient comfort.

The typical nebulized medication is a water-soluble substance which can form relatively dilute aqueous solutions. This is desired, due to the relatively large volumes of solution which will be entrained in an inhaled air stream, and to the very small quantities of drug which will typically be delivered  
20 in a single treatment. Handling of a drug solution is quite uncomplicated: a desired volume of a solution (usually aqueous) is either nebulized directly or is measured into a larger volume of sterile water for nebulization.

However, some very useful inhalation drugs have little or essentially no water solubility. Examples of such drugs are corticosteroids, typically  
25 administered in the treatment of asthma by inhalation from pressurized metered dose inhalers, either in alcohol solution or as suspended micronized particles, or from dry powder inhalers of various types.

It is also known to form an aqueous suspension of drug particles, for nebulization. Commercial products, which have not been made available in all  
30 countries, currently include beclomethasone dipropionate (sold by Glaxo under the trade name BECOTIDE) and budesonide (formulated with a citrate-citric acid buffer and Polysorbate 80 surfactant, and sold by Astra under the trade

name PULMICORT). Corticosteroids have also been formulated in liposome suspensions in aqueous media, for nebulizer delivery, as in United States Patent 5,192,528.

5 The therapeutic advantages of the corticosteroid mometasone furoate for treating disorders of the lower airway make this drug a desirable candidate for delivery by nebulization. Since this drug is not soluble in aqueous media, it has become necessary to develop aqueous suspensions for nebulization.

### SUMMARY OF THE INVENTION

10

The invention comprises an aqueous suspension of micronized mometasone furoate monohydrate, also containing a nonionic surfactant, a soluble salt and optionally a pH buffer. Preferred surfactants are those known as polysorbates. The soluble salt may be sodium chloride, in amounts  
15 needed to render the solution phase isotonic. When the buffer is present, it preferably will be chosen to maintain a solution pH between about 3 and about 7.

### BRIEF DESCRIPTION OF THE DRAWING

20

Fig. 1 is a graphical representation of results from the experiment of Example 3.

### DETAILED DESCRIPTION OF THE INVENTION

25

Percentages expressed herein are meant to indicate percent by weight, unless the context clearly dictates otherwise.

The suspension formulations of the invention may be delivered to a patient using any of the usual nebulizer devices. Typical commercial nebulizer  
30 devices produce dispersions of droplets in gas streams by one of two methods. Jet nebulizers use a compressed air supply to draw up a fluid by venturi action and introduce it into a flowing gas stream, after which the fluid is

caused to impact one or more stationary baffles to remove excessively large droplets. Ultrasonic nebulizers use an electrically driven transducer to subject a fluid to high-frequency oscillations, producing a cloud of droplets which can be entrained in a moving gas stream; these devices are less preferred for  
5 delivering suspensions. There are hand-held nebulizers which atomize the fluid with a squeeze bulb air supply, but the more widely used equipment incorporates an electrically powered compressor or connects to a cylinder of compressed gas. Although the various devices which are commercially available vary considerably in their delivery efficiency for a given medicament,  
10 they all are useful for the treatment of the present invention; it is necessary for the prescriber to specify an exact amount of medicament formulation which is to be charged to each particular device, since their respective outputs of respirable droplets are far from identical.

Suspension formulations suitable for nebulization must, of course,  
15 contain solid particles of a respirable size (e.g., preferably averaging less than about 5  $\mu\text{m}$  in the largest dimension and more preferably averaging less than about 2  $\mu\text{m}$ ) and must maintain their suspended particle size distribution during storage. In addition, the particle-containing droplets formed during nebulization of the formulations must have appropriate sizes for deposition in  
20 the desired area of the respiratory system.

Since the formulations of the invention are to be inhaled, it is necessary that they be free of pathogenic organisms. Thus, they may be prepared and handled under sterile conditions, or may be sterilized before or after packaging. In addition, or in lieu of sterilization, a preservative may be  
25 incorporated to minimize the possibility of microbial contamination. In addition, all components of the formulations must be chosen for inhalation safety, as the treated tissues are quite sensitive to irritants; it is commonly known that many of the common preservatives have a considerable potential for causing irritation.

30 The inventive formulations comprise water, mometasone furoate monohydrate, a nonionic surfactant, a soluble salt and optionally a pH buffer.

Water for use in the formulations should meet or exceed the applicable regulatory requirements for use in inhaled drugs. Specifications established by the *United States Pharmacopoeia* for "Sterile Water for Injection" or "Sterile Water for Inhalation" are examples of water suitable for use to prepare  
5 formulations of the invention.

Mometasone furoate is a corticosteroid having the chemical name 9 $\alpha$ ,21-Dichloro-11 $\beta$ ,17-dihydroxy-16 $\alpha$ -methylpregna-1,4-diene-3,20-dione 17-(2-furoate), and is currently marketed by Schering Corporation in cream and lotion formulations for the treatment of dermatologic conditions. Information  
10 concerning the preparation and properties of mometasone furoate is given in United States Patent 4,472,393. This compound may be used to prepare mometasone furoate monohydrate for use in the present invention. Information concerning the preparation and properties of mometasone furoate monohydrate is given in PCT International Application WO 92/04365.

15 In general, the concentration of mometasone furoate included in the suspension formulation will depend upon the dose to be delivered to the patient, ease of handling and the characteristics of the nebulizer equipment, as the devices vary considerably in their suspension capacities and nebulization efficiencies. Typical suspensions may contain as much as about  
20 5 mg/mL of mometasone furoate, although lower concentrations, such as 50  $\mu$ g/mL to 1 mg/mL are more customary for most equipment.

Surfactants are frequently categorized by their chemical nature, i.e., as cationic, anionic or nonionic. Cationic surfactants, such as cetyl pyridinium chloride, and anionic surfactants, such as docusate sodium, do not appear to  
25 provide proper dispersions of particles in the formulations.

Many nonionic surfactants are suitable for maintaining the particulate suspensions of the invention. These include surfactants identified as "polysorbates" in the *CTFA International Cosmetic Ingredient Dictionary*; such  
30 surfactants are mixtures of fatty acid esters (predominately monoesters) of sorbitol and sorbitol anhydrides, condensed with ethylene oxide. Although these surfactants vary widely in their hydrophilic-lipophilic balance ("HLB") numbers, they all appear to function well in the invention.

Commercially available polysorbates which are useful in the invention include those listed in the following table, which shows the CTFA designation (Polysorbate number), identity of the fatty acid used to produce the material and the number of moles of ethylene oxide reacted with each mole of ester.


5 Compositions identified with an asterisk are predominately triesters.

	<u>Polysorbate</u>	<u>Acid</u>	<u>Moles EtO</u>
	20	Lauric	20
10	21	Lauric	4
	40	Palmitic	20
	60	Stearic	20
	61	Stearic	4
	65*	Stearic	20
15	80	Oleic	20
	81	Oleic	5
	85*	Oleic	20

20 In general, Polysorbate surfactants will be present in a formulation at about 50 to 500 µg/mL. When the surfactant concentration is below about 20 µg/mL, the particles tend to form cakes which are not easily redispersed.

Useful surfactants also include the "Poloxamers," which are block polymers of polyoxyethylene and polyoxypropylene, generally corresponding to the following formula:

25



Representative commercially available poloxamer surfactants are listed in the following table, wherein the CTFA designation (Poloxamer number) and average values of x, y and z are given.

30



	<u>Poloxamer</u>	x	y	z
5	101	2	16	2
	105	11	16	11
	108	46	16	46
	122	5	21	5
	123	7	21	7
10	124	11	21	11
	181	3	30	3
	182	8	30	8
	183	10	30	10
	184	13	30	13
15	185	19	30	19
	188	75	30	75
	212	8	35	8
	215	24	35	24
	217	52	35	52
20	231	6	39	6
	234	22	39	22
	235	27	39	27
	237	62	39	62
	238	97	39	97
25	282	10	47	10
	284	21	47	21
	288	122	47	122
	331	7	54	7
	333	20	54	20
30	334	31	54	31
	335	38	54	38
	338	128	54	128
	401	6	67	6
	402	13	67	13

403	21	67	21
407	98	67	98

5 Poloxamer surfactants are used at concentrations similar to those for the Polysorbates, although certain members are useful at concentrations up to about 1 mg/mL.

In general, the chosen surfactant should not materially increase the viscosity of the suspension formulation, since the efficiency of the nebulization process is particularly sensitive to viscosity. Many nonionic surfactants are  
10 useful for preparing inhalation and/or injectable drug formulations, and any of these should be suitable for use in the present invention.

The formulations further include a soluble salt. This salt performs at least two functions: it minimizes the effects of the inhaled formulation on the normal cell fluid balance of airway cells and also stabilizes the suspension of  
15 medicament. For the first function, it is preferred to use sufficient salt concentrations to render the formulation isotonic; sodium chloride and potassium chloride are preferred for this purpose. It has been found that adequate suspension stability is produced by isotonic concentrations (i.e., about 0.9 weight percent) of sodium chloride, although concentrations about  
20 0.2 to about 2 weight percent are useful. Any physiologically compatible alkali metal or alkaline earth metal soluble salt can be used in the present invention.

Optionally, the formulations will contain a pH buffer, to maintain the formulation pH between about 3 and about 7. It has been found that stability of the drug (as measured by the absence of degradation reaction products) in  
25 suspension is improved by maintaining pH conditions below about 6. For reasons of tissue compatibility, excessively acidic products are not desired, so the pH should not be made to be below about 3. Some experimentation may be needed to qualify specific buffers for use in the invention: phosphate buffers in concentrations of 1 to 50 millimolar do not appear to adequately prevent  
30 caking of the particulates in the suspension when there is no added soluble salt. A citrate-citric acid buffer, maintaining pH between about 4 and about 5,

has been used with particularly good effect for both maintaining pH during storage and preventing any particulate caking in the absence of soluble salts.

The citrate-citric acid buffer may be present in suspension formulations at concentrations at least about 2 and up to about 50 millimolar. While the literature has some reports of cough being induced by such buffer systems, this seems to occur primarily at the 150-200 millimolar level, although one report attributed cough to only a 35 millimolar concentration.

Sterility or adequate antimicrobial preservation of the final packaged formulation is needed for patient protection. The use of antimicrobial preservatives is less desirable, since certain of these have been associated with adverse clinical effects, such as bronchospasm. Alternative processes which may be considered for achieving sterility usually will not include sterilization steps for the micronized drug substance or formulation, since it has been found that the drug undergoes degradation under the influence of gamma-ray irradiation and sterilizing heat conditions. Sterilization by filtration ordinarily will not be feasible, due to the suspension nature of the formulation. Thus, it is preferred to produce the mometasone furoate monohydrate under sterile conditions, conduct the drug micronization in a sterile environment, and perform a sterile packaging operation.

Methods are known for reducing particle sizes into the micrometer range, including mechanical milling, application of ultrasonic energy and other techniques. Mechanical milling frequently generates high surface temperatures on the particles, and this is undesirable for mometasone furoate monohydrate which tends to lose some part of its hydration under the influence of high temperatures. Ultrasonic techniques are quite slow in their action, generally requiring very long processing times, but are capable of producing acceptable suspensions.

Suspensions of drug particles can rapidly undergo particulate size reduction when subjected to "jet milling" (high pressure particle in liquid milling) techniques. A presently preferred jet milling procedure for producing the formulations of the invention involves the use of the "Microfluidizer" system sold by Microfluidics International Corporation of Newton, Massachusetts,

U.S.A. This device divides a fluid stream, flowing under high pressures (up to about 40,000 pounds per square inch, or  $2.76 \times 10^8$  newton/meter<sup>2</sup>), between two separate microchannel paths and then recombines them from generally perpendicular directions to create very high shear, impact and cavitation forces. By continuously recirculating suspensions through the system for a predetermined time period, it is possible to reproducibly create desired distributions of micron- and submicron-sized particles. Since the particles are always completely surrounded by liquid, their surfaces will not develop high temperatures under the influence of the size reduction forces, and the hydration water in the drug crystals will remain intact. Other useful equipment which utilizes related technology is available from Avestin Inc., Ottawa, Ontario, Canada.

The following examples are provided to further illustrate and explain certain aspects of the invention, and are not intended to limit the scope of the invention, as defined by the appended claims, in any manner.

#### EXAMPLE 1

Sterile mometasone furoate monohydrate is prepared by a procedure including the following steps:

- (1) charge 250 grams mometasone furoate to a dissolution vessel containing 4250 mL of acetone, and mix to form a clear solution;
- (2) pump the solution through a sterilizing filter, such as a filtration medium having pores not exceeding 0.2  $\mu$ m in diameter, into a sterile precipitation vessel equipped with means for stirring and means for heating the contents (note that sterile equipment and a sterile environment must be used for all subsequent steps);
- (3) heat the sterile solution to about 45-50°C and slowly add, over about 15 minutes, 1000 mL of sterile purified water while maintaining the temperature;
- (4) while maintaining the elevated temperature, slowly add an additional 750 mL of the water, with stirring over about 30 minutes;

(5) continue the stirring and maintain the temperature for an additional 30 minutes, during which a precipitate will begin to form;

(6) slowly add an additional 5250 mL of the water over about 60 minutes, while maintaining a rapid stirring and the elevated temperature;

5 (7) continue stirring at the elevated temperature for about 60 minutes;

(8) cool the mixture to ambient temperature, with continued stirring;

(9) filter the precipitate (mometasone furoate monohydrate) and wash it with two 500 mL portions of the sterile purified water; and

(10) dry in a vacuum oven at 30-35°C for 12-24 hours.

10

The dried sterile mometasone furoate monohydrate product should have a water content, as measured by a standard Karl Fischer titration, of 3.3 percent by weight and contains 96.7 percent by weight mometasone furoate.

15

#### EXAMPLE 2

A 40 liter batch of a sterile aqueous suspension of mometasone furoate monohydrate is prepared using the following procedure:

20 (1) sequentially charge 2.0 grams of Polysorbate 80, 7.24 grams of citric acid monohydrate and 13.4 grams of sodium citrate dihydrate to about 1000 grams of purified water in a vessel equipped for stirring, stir to form a solution having a pH of  $4.5 \pm 0.5$ , add additional purified water to make 1315 grams of solution and filter the solution under pressure through a 0.2  $\mu\text{m}$  sterilizing filter into a sterile recirculation vessel, equipped for stirring;

25 (2) add 360 grams of sodium chloride to about 1800 grams of purified water, stir to dissolve, add additional purified water to make 2000 grams of solution and filter under pressure through a 0.2  $\mu\text{m}$  sterilizing filter into a sterile vessel;

30 (3) add 21.73 grams of mometasone furoate monohydrate, prepared as in Example 1, to the sterile solution of step (1) and commence stirring the vessel contents to form a suspension;

(4) pass the mixture of the preceding step through a sterilized Model 210B-EH pilot-scale Microfluidizer operating at  $17500 \pm 500$  pounds per square inch ( $1.21 \times 10^8$  newton/meter<sup>2</sup>  $\pm 3.45 \times 10^6$  newton/meter<sup>2</sup>) gauge pressure for  $40 \pm 5$  minutes while returning the Microfluidizer discharge into the stirred recirculation vessel ;

(5) transfer the micronized mometasone furoate suspension from the recirculation vessel to the vessel of step (2);

(6) rinse the Microfluidizer with sterile purified water and add the rinse water to the suspension formed in the preceding step, then add a sufficient additional quantity of the water to form a suspension weighing 40100 grams; and

(7) fill individual sterile containers with a desired amount of suspension (containing 0.5 mg of mometasone furoate per milliliter and having a specific gravity of 1.003 g/cm<sup>3</sup>) for use in a nebulizer.

The weight for the mometasone furoate monohydrate includes a 5 percent overcharge to compensate for manufacturing losses.

### EXAMPLE 3

Using the procedure of the preceding example, a suspension is prepared which has the following composition and a pH about 4.5:

Mometasone furoate *	500 µg
Polysorbate 80	50 µg
Citric acid monohydrate	181 µg
Sodium citrate dihydrate	335 µg
Sodium chloride	9 mg
Water for injection, USP	to make 1 mL

\* From mometasone furoate monohydrate

A particle size distribution is determined for the suspension by a laser light scattering technique. A Malvern 2600 instrument, manufactured by Malvern Instruments, Malvern, Worcestershire, United Kingdom, is set up with a liquid flow cell and a 63 mm lens, and operated in its "particle in liquid" mode with water (containing a small amount of Polysorbate 80 as a wetting agent) as the vehicle. Drug suspension is added until an optimum light obscuration is achieved, then the measurements are obtained. Data are calculated and expressed on a volume distribution basis, and are graphically represented as shown in Fig. 1. This suspension has a median particle size of 1.24  $\mu\text{m}$  and a mean particle size of 1.34  $\mu\text{m}$ .

#### EXAMPLE 4

Commercially available nebulizers are used to determine the drug delivery characteristics for the suspension of the preceding example and two commercial suspension products: BECOTIDE beclomethasone dipropionate suspension (Glaxo) and PULMICORT budesonide suspension (Astra). The nebulizers are WHISPER JET (Marquest Medical Products, Englewood, Colorado, U.S.A.) and PARI JET (PARI Respiratory Equipment, Inc., Richmond, Virginia, U.S.A.). Suspensions are placed into the nebulizers in 3 mL amounts, and the equipment is connected to a compressor and operated according to the manufacturers' instructions. Nebulized drug is directed into the top of a 500 mL separatory funnel containing a 1 gram plug of cotton, and the lower outlet of the funnel is connected to a vacuum line. After the nebulizer becomes dry, the vacuum line is disconnected and the funnel (with the plug) is washed with 25 mL of a solvent for the drug (e.g., methanol), which is then collected and analyzed for the drug by high performance liquid chromatography to determine the percentage of originally charged drug which was delivered to the funnel.

Results are obtained as follows, where the values are averages of four determinations:

		<u>Percent Delivered</u>	
		<u>Pari Jet</u>	<u>Whisper Jet</u>
5	<u>Product</u>		
	Example 3	32.9	23.6
	Becotide	23.5	13.4
	Pulmicort	31.9	18.1

EXAMPLE 5

- As in preceding Example 3, the following suspension formulations are prepared, each containing sufficient sterile water to make a final volume of 1 mL:

	Formula	<u>5A</u>	<u>5B</u>	<u>5C</u>
	Mometasone furoate, µg	250	500	500
15	Polysorbate 80, µg	50	500	50
	Citric acid monohydrate, µg	181	181	80
	Sodium Citrate dihydrate, µg	335	335	470
	Sodium chloride, mg	9	9	9

- The mometasone furoate content is provided by mometasone furoate monohydrate.

EXAMPLE 6

- As in preceding Example 3, the following suspension formulations are prepared, each containing sufficient sterile water to make a final volume of 1 mL:

	Formula	<u>6A</u>	<u>6B</u>	<u>6C</u>
30	Mometasone furoate, µg	500	500	750
	Polysorbate 80, µg	50	50	50
	Citric acid monohydrate, µg	294	181	181



Sodium Citrate dihydrate, µg	174	335	335
Sodium chloride, mg	9	4.5	18

The mometasone furoate content is provided by mometasone furoate  
5 monohydrate.

## WHAT IS CLAIMED IS:

1. A nebulizer suspension comprising water, mometasone furoate monohydrate, a nonionic surfactant and a soluble salt.
2. The suspension of claim 1, wherein mometasone furoate monohydrate comprises about 50 micrograms to about 5 milligrams, per milliliter.
3. The suspension of claim 1, wherein the surfactant comprises a Polysorbate surfactant.
4. The suspension of claim 1, wherein the surfactant comprises Polysorbate 80.
5. The suspension of claim 1, wherein the surfactant comprises a Poloxamer surfactant.
6. The suspension of claim 1, wherein the surfactant comprises about 50 micrograms to about 1 milligram, per milliliter.
7. The suspension of claim 1, wherein the salt comprises sodium chloride.
8. The suspension of claim 1, wherein the salt comprises about 0.2 to about 2 percent by weight.
9. The suspension of claim 1, further including a pH buffer.
10. The suspension of claim 9, wherein the buffer comprises a citric acid-citrate buffer.

11. The suspension of claim 9, wherein the buffer maintains aqueous phase pH values about 3 to about 7.
12. The suspension of claim 9, wherein the buffer maintains aqueous phase pH values about 3 to about 6.
13. The suspension of claim 9, wherein the buffer maintains aqueous phase pH values about 4 to about 5.
14. The suspension of claim 1, wherein solid particles have average sizes less than about 5  $\mu\text{m}$ .
15. The suspension of claim 1, wherein solid particles have average sizes less than about 2  $\mu\text{m}$ .
16. A process for producing a nebulizer suspension, comprising combining ingredients including water, mometasone furoate monohydrate, a nonionic surfactant and a soluble salt and subjecting the combination to particle size reduction by ultrasonication or by jet milling.
17. The process of claim 16, wherein the combination further includes a pH buffer.
18. The process of claim 16, wherein particle size reduction is continued to produce solid particles having sizes less than about 10  $\mu\text{m}$ .
19. The process of claim 16, wherein particle size reduction is continued to produce solid particles having average sizes less than about 5  $\mu\text{m}$ .
20. The process of claim 16, wherein particle size reduction is continued to produce solid particles having average sizes less than about 2  $\mu\text{m}$ .

21. A method for treating airway disorders, comprising administering by nebulization to surfaces of the airway a treatment-effective amount of the suspension of claim 1.

22. A method for treating airway disorders, comprising administering by nebulization to surfaces of the airway a treatment-effective amount of a suspension prepared by the process of claim 16.

# INTERNATIONAL SEARCH REPORT

Internat	Application No
PCT/US	98/20480

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 6 A61K31/58 A61K9/12 A61K9/72

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 04365 A (SCHERING CORP) 19 March 1992 cited in the application	1-4, 6, 9-13
Y	see page 7, line 31 - page 8, line 18; example 3 ---	5, 7, 8, 14-22
Y	WO 95 20393 A (SCHERING CORP) 3 August 1995 see page 11, line 8 - page 13, line 18 ---	5, 7, 8, 14-22
Y	EP 0 653 205 A (SCHERING CORP) 17 May 1995 see abstract see page 5, line 42 - line 46; claims 1-14; example XVII see example XVIII see example XXVI -----	5, 7, 8, 14-22

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

24 February 1999

03/03/1999

Name and mailing address of the ISA

Authorized officer

European Patent Office, P.B. 5618 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel: (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Tzschoppe, D

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat Application No

PCT/US 98/20480

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9204365 A	19-03-1992	AT 113604 T	15-11-1994
		AU 663471 B	12-10-1995
		AU 8497491 A	30-03-1992
		BG 60755 B	29-02-1996
		CA 2091360 A,C	11-03-1992
		CN 1059911 A,B	01-04-1992
		CZ 9300383 A	19-01-1994
		CZ 281318 B	14-08-1996
		DE 69104991 D	08-12-1994
		DE 69104991 T	20-04-1995
		DK 548114 T	30-01-1995
		EP 0548114 A	30-06-1993
		ES 2065701 T	16-02-1995
		FI 931031 A	09-03-1993
		HK 185996 A	11-10-1996
		HR 920383 A	30-06-1998
		HU 64361 A	28-12-1993
		HU 213401 B	30-06-1997
		IE 67056 B	21-02-1996
		IL 99437 A	29-05-1995
		JP 7025789 B	22-03-1995
		KR 9613445 B	05-10-1996
		MX 9203396 A	31-07-1992
		NO 300548 B	16-06-1997
		OA 9772 A	30-11-1993
		PL 165803 B	28-02-1995
		PT 98905 A,B	30-09-1992
		SI 9111497 A	30-04-1998
WO 9520393 A	03-08-1995	AU 691880 B	28-05-1998
		AU 1727195 A	15-08-1995
		CA 2182086 A	03-08-1995
		CN 1139384 A	01-01-1997
		CZ 9602191 A	11-12-1996
		EP 0740550 A	06-11-1996
		FI 962828 A	12-07-1996
		HU 74884 A	28-02-1997
		JP 9501700 T	18-02-1997
		NO 963132 A	26-09-1996
		PL 315575 A	12-11-1996
		SG 47387 A	17-04-1998
		SK 82296 A	05-03-1997
		US 5837699 A	17-11-1998
		ZA 9500637 A	26-07-1995
EP 0653205 A	17-05-1995	EP 0656205 A	07-06-1995
		AT 132368 T	15-01-1996
		AU 2178992 A	12-01-1993
		CA 2111003 A	23-12-1992
		CN 1067579 A	06-01-1993
		CZ 9302713 A	13-07-1994
		DE 69207409 D	15-02-1996
		EP 0518601 A	16-12-1992
		EP 0587790 A	23-03-1994
		FI 935463 A	07-12-1993
		HU 67445 A	28-04-1995
		JP 6508149 T	14-09-1994
		MX 9202751 A	01-12-1992

### Information on patent family members

PCT/US 98/20480

Form PCT/ISA210 (patent family annex) (July 1992)